Journal of Psychoactive Drugs, 00 (00), 1–8, 2015
Copyright © Taylor & Francis Group, LLC
ISSN: 0279-1072 print / 2159-9777 online
DOI: 10.1080/02791072.2015.1094156
The Psychopharmacology of
±3,4 Methylenedioxymethamphetamine
and its Role in the Treatment of
Posttraumatic Stress Disorder
Timothy Amoroso, B.S.
5
10
15
Abstract —Prior to 1985, ± 3,4-methylenedioxymethamphetamine (MDMA) was readily used as
a psychotherapeutic adjunct. As MDMA became popular in treating various psychiatric illnesses
by mental health professionals, the public started to abuse the MDMA-containing recreational drug
“ecstasy.” This alarmed the DEA, which led to emergency scheduling of MDMA as a Schedule I drug.
Due to its scheduling in 1985, human research and clinical use has been limited. The majority of
research on MDMA has been focused on the drug’s potential harmful effects rather than its possible
therapeutic effects. The limitations on retrospective human studies and preclinical animal models of
MDMA neurotoxicity are examined in this analysis. New research has shown that MDMA, used as
a catalyst in psychotherapy, is effective in treating posttraumatic stress disorder (PTSD). This review
also examines the psychopharmacological basis for the efficacy of MDMA-assisted psychotherapy.
Specifically, the brain regions involved with both PTSD and those activated by MDMA (i.e., amygdala, anterior cingulate cortex, and hippocampus) are examined. Also, the possible neurochemical
mechanisms involved in MDMA’s efficacy in treating PTSD are reviewed.
Keywords — MDMA, MDMA-assisted psychotherapy, posttraumatic stress disorder, PTSD
20
25
±3,4-methylenedioxymethamphetamine
(MDMA)
was originally synthesized in 1912 by Merck as an intermediate for a drug designed to stop bleeding. From 1912 to
the mid-1970s, MDMA was not well known or studied
scientifically. David Nichols and Alexander Shulgin were
the first biochemists to study the psychoactive properties
of the drug in humans. In the first clinical study of
MDMA, the two researchers found that the drug produced
“an easily controlled altered state of consciousness with
emotional and sensual overtones” (Shulgin and Nichols
1978). At that point, Shulgin suggested to a group of
psychiatrists that the drug might have a therapeutic
potential in treating mental disorders. Leo Zeff was the
first noted psychologist to use MDMA as an adjunct to
psychotherapy and found impressive results prior to any
controlled clinical trials (Pentney 2001). By the 1980s, at
least 150 therapists were using MDMA in their practice
and an estimated 500,000 therapy and personal growth
sessions had been conducted using MDMA as a therapeutic
catalyst (Stolaroff 1997; Rosenbaum and Doblin 1991).
Unfortunately, just as the drug was becoming well known
in the clinical sphere, it was also being used recreationally
under the name “ecstasy.” In 1985, the Drug Enforcement
Administration decided to emergency schedule MDMA
Research Assistant, Department of Psychology, University of New
Hampshire, Durham, NH.
Please address correspondence to Timothy Amoroso, Research
Assistant, Department of Psychology, University of New Hampshire,
83 Main Street, Durham, NH 03824, USA; email: timamoroso@gmail.
com
Journal of Psychoactive Drugs
1
Volume 00 (00), Xxxx – Xxxx 2015
30
35
40
Amoroso
45
50
55
60
65
70
75
80
Mechanisms of MDMA-Assisted Psychotherapy
and categorized it as a Schedule I drug. This legislation
caused all clinical research to be terminated or severely
restricted while the illicit use of the drug continued and,
in some years, increased (Sessa and Nutt 2007). Also,
the therapists that were using MDMA in their practices
were either forced to discontinue using the drug with their
clients or ignore the law and risk legal punishment.
In the mid-1990s, the majority of research done
on MDMA was focused on the potential dangers of
the drug. Many studies found that MDMA had neurotoxic effects in animal models and in human retrospective studies. However, some of the erroneous beliefs
about MDMA revolve around flawed studies. For instance,
George Ricaurte of Johns Hopkins University published a
paper showing that MDMA produced severe dopaminergic neurotoxicity and death in primates. This paper was
questioned because it estimated that nearly a million people
every weekend use MDMA with a very low rate of complications (Mithoefer, Jerome, and Doblin 2003). Ricaurte’s
paper was later retracted from Science because it was found
that methamphetamine was used in the experiment rather
than MDMA as reported (Ricaurte et al. 2002). Although
there are risks involved with the use of any drug, this article will not focus on the potential risks of MDMA use. The
Food and Drug Administration has already concluded that
MDMA has an acceptable risk to benefit ratio in a clinical
setting (Doblin 2002).
This article will highlight the clinical use of MDMA.
Specifically, it will review the subjective effects of the
drug and the receptors responsible for those effects, the
neuroanatomical regions of the brain that are activated by
MDMA, and how the psychopharmacology of MDMA is
linked to its efficacy in treating people with posttraumatic
stress disorder. However, because there is still ongoing
debate in the literature about the safety and efficacy of
MDMA, the limitations of current human and animal
research will also be discussed.
and purity, as well as preexisting or underlying mental disorders. An important issue is that there is often a selection
bias when recruiting participants because heavy drug users
from the rave culture are typically invited to participate in
these studies. For example, Schilt et al. (2008) conducted
a study measuring the cognitive deficits caused by ecstasy
use in participants that had an average lifetime exposure
of 327 tablets (range: 15–2000), while only 20–30% of
ecstasy users consume more than 25 tablets in their lifetime (De Win et al. 2005). It may be argued that research
like this is studying a reckless personality type rather than
the long-term neurocognitive effects of a drug.
Many studies have found that MDMA does affect
5-HT metabolism and decreases 5-HIAA concentrations
in cerebral spinal fluid (Stanley, Traskman-Bendz, and
Dorovini-Zis 1985; Wode-Helgodt and Sedvall 1978).
However, some studies have failed to link these findings to behavioral or long-lasting psychological changes
from MDMA use. One study employed moderate users
(22–50 lifetime exposures) and heavy users (60–240) of
ecstasy with minimal lifetime exposure to other drugs. Few
differences were found between ecstasy users and nonusers on a battery of neuropsychological tests. However,
heavy users did show some differences on measures of
impulsivity and mental processing (Halpern et al. 2004).
These findings suggest that there may be other factors, such
as impulsivity or poly-drug use, that contribute to the neurocognitive deficits found among ecstasy users in studies
that do not control for poly-drug use.
Some retrospective studies have been unable to find
neurocognitive deficits in ecstasy users. Back-Madruga
et al. (2003) recruited 22 recreational ecstasy users and
compared them to 28 controls on a comprehensive battery
of neuropsychological tests and found no significant differences. However, they did find that ecstasy users who
reported heavy use had lower scores on non-verbal memory. It should be noted that this might be more closely
correlated to a drug-seeking and impulsive personality type
rather than the drug itself. It may be intuitive to think
that MDMA’s toxic effects on the brain should be studied in animal models, but even some of these studies have
inherent limitations.
Many animal studies do show serotonergic neurotoxicity after administering MDMA to rats. However, some
of these studies may have limited external validity due to
methodological issues. For instance, doses of the drug used
in animal studies are often much higher compared to what
humans would typically consume. Also, the drug is typically administered more frequently (leaving little time to
recover) and intravenously, which is virtually unheard of in
humans. For instance, Commins et al. (1987) administered
10, 20, or 40 mg/kg (compared to the typical 1.5 mg/kg in
humans) twice a day for four days (which is only representative of severe drug abuse or binging), and found damaged
axon terminals in the striatum and somatosensory cortex
A NOTE ON THE INTERPRETATION OF
COGNITIVE DEFICITS IN MDMA USERS
85
90
95
Since there is debate about the safety of MDMA,
it may be necessary to mention some of the shortcomings of these findings. Andrew Parrott (2013) has written
extensively on the neurocognitive effects produced by
ecstasy, which include: deficits in retrospective memory,
higher cognition, reduced serotonin transporter levels in
the cerebral cortex, disturbed sleep architecture, and other
behavioral and psychiatric problems. However, most of
the studies exploring these effects on humans should be
read with caution because they have many methodological flaws. For example, most employ non-randomized and
retrospective methodologies, which have inherent biases.
Also, it is difficult to control for poly-drug use, drug dose
Journal of Psychoactive Drugs
2
Volume 00 (00), Xxxx – Xxxx 2015
100
105
110
115
120
125
130
135
140
145
150
Amoroso
155
160
Mechanisms of MDMA-Assisted Psychotherapy
in rats. In addition, it has been found that there are large
differences in MDMA metabolism and in the formation of
neurotoxic metabolites between rats, non-human primates,
and humans (De La Torre and Farré 2004).
Although MDMA has been widely studied, there is
still debate on its level of neurotoxicity and its implicated
dangers. However, the FDA has deemed it safe enough for
clinical research to be conducted in the treatment of PTSD.
Importantly, none of the clinical trials employing rigorous
experimental controls have found long-term neurocognitive
deficits in their participants.
prefrontal cortex in rats but is attenuated with the administration of fluoxetine. SSRIs also inhibit the 5-HT-induced
behavioral effects of MDMA (Callaway, Wing, and Geyer
1990), and protect against 5-HT-induced neurotoxicity
(Schmidt 1987). These findings show the strong action of
MDMA on the 5-HT transporter. However, only human
studies can reveal the receptors involved in the more
nuanced psychological effects of the drug.
Matthias Lietchi and Franz Vollenweider have conducted a series of double-blind placebo-controlled studies to determine the receptors responsible for the specific psychological effects of acute MDMA administration
using pretreatments of three different receptor ligands.
In one of these studies, the researchers used haloperidol
(1.4 mg, i.v.), a D2 antagonist, as a pretreatment to orally
administered MDMA (1.5 mg/kg, p.o.). They found that
haloperidol attenuated the euphoric and mania-like effects
of MDMA but had no effect on other subjective effects
(Liechti and Vollenweider 2000a). These findings show
that MDMA’s action on the D2 receptor is responsible
for the amphetamine-like effects of the drug. Another of
these studies used the drug citalopram (SSRI that acts on
the 5-HT transporter). When participants were pretreated
with citalopram intravenously (40 mg), prior to orally
administered MDMA (1.5 mg/kg), most of the psychological and physiological effects of MDMA were attenuated
(Liechti and Vollenweider 2000a). In other words, the 5HT transporter modulates the acute effects of MDMA,
which include reduced anxiety, acute anti-depression, and
increased insight, as well as slightly increased heart rate
and blood pressure. Ketanserin, a 5-HT2A/C antagonist,
was also used to determine how MDMA interacted with
these receptors. When participants were pretreated with
Ketanserin (50 mg p.o.) and 1.5 mg/kg MDMA, there were
statistically significant reductions in sensory and perceptual
amplification, but these didn’t attenuate other aspects of the
drug effect (Liechti et al. 2000b). Interestingly, part of the
drug effect is dependent on the influx of the neuropeptide
oxytocin.
One of the hallmark effects of MDMA use is the feeling of closeness and affiliation. It has been established
in both animal studies and human studies that this is
the result of an increased release of oxytocin. Thompson
et al. (2007) found that when Winstar rats are injected
with MDMA (5 mg/kg, i.p.), they spend more time laying
closer together. After the rats were perfused, Fos immunochemistry revealed that oxytocin-containing neurons were
activated in the supraoptic and paraventricular nuclei of the
hypothalamus. In humans, it has been found that MDMA
significantly increases blood plasma levels of oxytocin, and
the subjective pro-social feelings are positively correlated
to the oxytocin levels in the blood (Dumont et al. 2009).
The increased sociability and feelings of closeness with
others may also be due to the brain regions activated during
the use of the drug.
PSYCHOPHARMACOLOGY OF MDMA
165
170
175
180
185
190
195
200
MDMA is a ring-substituted methamphetamine typically used in the hydrochloride salt form, which is an offwhite colored powder (Shulgin 1986). The drug has structural similarities to both amphetamine and the psychedelic
mescaline. MDMA has traditionally been considered a
psychedelic amphetamine; however, it has been contended
that the drug may belong to a unique class of drugs
called “entactogens” (Nichols and Oberlender 1990). The
drug’s primary mechanism of action is on the 5-HT transporter, which results in excessive serotonin in the synaptic
cleft but also interacts with other neurotransmitter systems,
including dopamine and norepinephrine (Green, Cross, and
Goodwin 1995). MDMA also acts to increase the release
of oxytocin and vasopressin, which has been found to
produce acute pro-social behaviors in rats (Ramos et al.
2013). These specific mechanisms will be discussed in
more detail, but first the psychological effects of MDMA
will be noted.
Liester et al. (1992) interviewed 20 psychiatrists to
explore the phenomenological qualities of their personal
experiences with MDMA. They found that the positive
drug effects included sensory intensification, increased
awareness of emotions, changes in interpersonal relationships, and slight ego dissolution. The psychiatrists reported
that the negative effects of the drug included temporary
anorexia, trismus (jaw tension), bruxism (teeth grinding),
and motor restlessness. Many of the psychiatrists reported
that their MDMA use resulted in long-lasting improvements in their attitudes and behavior and the drug has a
potential as a therapeutic catalyst. Another study found
that when MDMA was given to participants (1.5 mg/kg
p.o.), the subjective effects included euphoria, a sense of
well-being, moderate de-realization, and heightened sensory awareness (Liechti et al. 2000a). These effects are
primarily mediated by the increased concentration of 5-HT
in the synaptic cleft, which was originally discovered in
preclinical animal models.
Animal studies have shown that serotonin reuptake
inhibitors (SSRIs) block the effects of MDMA. Gudelsky
and Nash (1996) found that MDMA produces increased
concentrations of extracellular 5-HT in the striatum and
Journal of Psychoactive Drugs
3
Volume 00 (00), Xxxx – Xxxx 2015
205
210
215
220
225
230
235
240
245
250
255
Amoroso
260
265
270
275
280
285
290
295
300
305
310
Mechanisms of MDMA-Assisted Psychotherapy
clusters characterize the disorder: re-experiencing symptoms, avoidance symptoms, and hyper-arousal symptoms.
These symptoms are often chronic and hard to treat. The
Veteran Affairs estimates that only 9.5% of veterans diagnosed with PTSD are actually receiving treatment (Seal
et al. 2010). This may be due to the marginal efficacy of
current pharmacotherapy and psychotherapeutic options.
Currently, only two pharmaceuticals are approved for treating PTSD: sertraline and paroxetine (Pollack et al. 2001).
Many psychotherapeutic options are available, but
some have high dropout rates. Prolonged exposure therapy
(PE) is thought to be the first-line treatment for PTSD, but
one study found that only 6.3% of veterans being treated
with psychotherapy are actually receiving trauma-centered
therapy (Shiner et al. 2013). This is likely due to the
emotionally demanding nature of exposure therapy, which
causes the dropout rates to hover around 30% (Cloitre
2009). Although Cognitive Processing Therapy (CPT) has
fewer completed clinical trials than PE, the treatment has
a lower dropout rate and a promising treatment response.
Monson et al. (2006) found that 40% of patients receiving
CPT no longer met criteria for PTSD, while only 16.6% of
patients dropped out of treatment prematurely. An emerging and somewhat controversial treatment for PTSD is Eye
Movement Desensitization Reprocessing (EMDR) therapy,
which shows comparable effects to behavioral therapies
(Bradley et al. 2014; Davidson et al. 2001; Van Etten et al.
1998). Even with the emerging therapies, PTSD remains a
chronic disorder and is difficult to treat.
First, trauma often affects the patient’s ability to
form trusting interpersonal relationships, which can affect
the “working alliance” between the patient and therapist
(Doukas et al. 2014). Another factor causing high dropout
rates in therapy is that many people with PTSD have a
small window of “optimal arousal” or “therapeutic threshold” (Foa et al. 1986). The reemerging thoughts brought
up in therapy often cause distress and sometimes dissociation in patients. MDMA, and its cumulative psychological
effects, has been found to mitigate some of these difficulties
in treating PTSD.
The efficacy of MDMA in treating PTSD may result
from a sum of its acute positive psychological effects.
Some clinicians have stated that in one MDMA-assisted
psychotherapy session, the patient can have results equivalent to five months of weekly therapy (Riedlinger and
Montagne 2001). The increased trust allows for the patient
to feel more comfortable sharing his or her trauma with
the therapist, while the increased insight, memory, and
attention allow patients to remember more details of the
trauma.
When traumatic memories emerge during the MDMA
experience, they are often seen as less threatening and can
result in memory reconsolidation (Doblin 2002). This idea
is supported by the study that found that negative autobiographical memories are perceived as less negative under
Bedi et al. (2009) conducted an fMRI study that
investigated the neural activation after participants were
given MDMA and responded to angry, happy, and neutral
faces. Participants that received MDMA (1.5 mg/kg, p.o.)
reported feelings of increased sociability and had attenuated left amygdala activation in response to angry faces.
Also, they found that there was increased activation in the
ventral striatum in response to happy faces. This shows that
the rewarding subjective effects (and possibly the therapeutic effects) of the drug may be due to reduced awareness of
negative social cues and the enhancement of positive social
cues.
Another fMRI study, of specific importance to the
clinical use in posttraumatic stress disorder, investigated
neural responses while processing autobiographical memories (Carhart-Harris et al. 2014). Participants ingested
100 mg MDMA (or placebo) and read their own favorite
and worst memories while inside an fMRI. The participants
that consumed MDMA reported that their worst memories
were less negative while their favorite memories were more
positive than those of the placebo group. The brain regions
that were attenuated while reading their worst memories
included the left anterior cingulate cortex, left amygdala,
and temporal cortex. In addition, the executive regions
of the hippocampus were activated while processing their
worst memories. This is important because it may highlight
some mechanisms that make MDMA an effective drug in
treating posttraumatic stress disorder.
The results of Carhart-Harris et al. (2014) show that
there is decreased amygdala activation and increased anterior cingulate cortex activation when participants who have
ingested MDMA respond to their worst memories. This
presents a mirror image of the neural activation shown by
people with posttraumatic stress disorder when faced with
fear. For instance, imaging studies show that when people
with posttraumatic stress disorder undergo a conditioned
fear paradigm, the left amygdala is strongly activated while
the anterior cingulate cortex is deactivated (Bremner et al.
2005). MDMA, by affecting the left amygdala, the anterior
cingulate cortex, and the executive areas of the hippocampus, may facilitate memory reconsolidation. These studies
were published while the safety and efficacy of MDMA
in treating posttraumatic stress disorder was being investigated by Michael Mithoefer in the United States and Peter
Oehen in Switzerland.
TREATING POSTTRAUMATIC STRESS
DISORDER WITH MDMA
In order to fully understand the possible mechanisms
that underlie MDMA’s effectiveness in treating posttraumatic stress, a rudimentary explanation of the disorder and
the complications in treating it must first be reviewed.
The DSM-IV defines PTSD as a stress and anxiety
disorder which follows a traumatic event. Three symptom
Journal of Psychoactive Drugs
4
Volume 00 (00), Xxxx – Xxxx 2015
315
320
325
330
335
340
345
350
355
360
365
Amoroso
370
375
380
385
390
395
400
405
410
415
Mechanisms of MDMA-Assisted Psychotherapy
the influence of MDMA (Carhart-Harris et al. 2014). Also,
the trust between patient and therapist may allow for more
material to be discussed. Grinspoon and Bakalar (1986)
have stated that “many patients report how much more they
trust the therapist and how much closer they feel to the therapist after one such session.” If, as many believe (Moras
and Strupp 1982; Gomes-Schwartz 1978), the strength of
the therapeutic alliance is the best predictor of a good outcome in therapy, this characteristic of MDMA would be
of very general usefulness. The increased trust and prosocial effects, which help form the therapeutic alliance,
are a result of the modulation of oxytocin. Both of these
factors—the increased trust and decreased anxiety associated with the trauma—are the proposed mechanisms of
therapeutic efficacy.
It is important to note that MDMA is thought to be
a therapeutic catalyst rather than a “cure” for PTSD. Nondrug psychotherapy sessions are conducted before and after
the MDMA-assisted psychotherapy. The initial non-drug
sessions are to prepare the patient for the MDMA experience, while the follow-up sessions are used to solidify
any insights gained or alleviate any difficulties experienced
during the drug therapy sessions (Mithoefer et al. 2011).
After the second MDMA session, the CAPS scores in the
treatment group decreased another 8.5 (SD = 6.5) points
compared to 7.3 (SD = 8.0) points for the placebo group.
At the two-month follow-up, the researchers found an
83.3% clinical response (defined as >30 point reduction in
CAPS) in the treatment group. At this point, the placebo
group was offered two open-label MDMA-assisted psychotherapy sessions. Seven of the eight members in the
placebo group volunteered for two MDMA-assisted psychotherapy sessions. This group showed a 100% clinical
response. In total, 16 of the 20 participants no longer met
criteria for PTSD at the two-month follow-up.
The researchers also conducted a long-term followup on the participants 17 to 74 months (mean = 45.4;
SD = 17.3) after exiting the study (Mithoefer et al. 2012).
They found that the clinical improvements were sustainable over time and there were no statistically significant
changes in the CAPS score. All of the participants except
two still no longer met criteria for PTSD. The profound
results from this study caused a surge in media attention,
as well as prompting other researchers to start planning
further investigations.
Oehen et al. (2012) conducted the second MDMAassisted psychotherapy study, since the drug was banned by
the DEA. This study recruited 12 treatment-resistant participants with PTSD. The design of the study was similar
to that of Mithoefer et al. (2011). One difference is that
there was an active placebo group, which received lowdose (25 mg) MDMA, while the treatment group received
125 mg MDMA.
This study reported a 23.5% reduction in CAPS scores
in the full-dose group but did not show statistically significant results (p = 0.066). However, it has been argued
that the statistical analysis used by the researchers was
not appropriate because of the small sample size (Chabrol
2013). Henri Chabrol contended that the effect size provides a more realistic picture of the results, which produced
a large effect (Cohen’s d = 1.08).
Both studies completed thus far have shown impressive results. However, the efficacy of MDMA-assisted psychotherapy needs further investigation. The two successful
Phase 2 clinical trials have shown that MDMA-assisted
psychotherapy is safe and effective, which will allow for
larger sample sizes in future Phase 3 trials.
CLINICAL TRIALS OF MDMA-ASSISTED
PSYCHOTHERAPY
In 2010, the first clinical trial of MDMA-assisted psychotherapy for PTSD was concluded after 19 years of
banned research. Mithoefer et al. (2011) conducted a randomized, placebo-controlled, double-blind, and crossover
design study consisting of 20 participants showing a large
effect size (Cohen’s d = 1.24). All the participants in the
study had chronic, treatment-resistant PTSD.
In this study, the participants were given a 125milligram capsule of MDMA in the morning prior to
an eight-hour psychotherapy session. Interestingly, there
were two therapists: a male psychiatrist and a female cotherapist. One practical reason for this is that, in case
one therapist had to be relieved, there was always another
present with the patient. Another reason is that often,
depending on the type of trauma, the patient can relate to
one sex better than the other. The therapy style used was
a modified form of LSD-assisted psychotherapy developed
by Stan Grof (Pahnke et al. 1971). After the eight-hour session, the patients stayed overnight at the facility to ensure
that there weren’t any complications after the drug effects
wore off, as well as to ensure there was support available if
it was needed.
The primary outcome measure was the Clinician
Administered PTSD Scale (CAPS) and was given to the
patients four days after the first and second drug sessions.
After the first MDMA session, the treatment group had a
41.4 (SD = 8.4) point reduction on the CAPS compared
to a 5.5 (SD = 10.3) point reduction in the placebo group.
Journal of Psychoactive Drugs
420
425
430
435
440
445
450
455
460
DISCUSSION
The psychopharmacology of MDMA has been extensively studied over the past 20 years. However, attempts
by scientists and the government to show the neurotoxic
effects in humans have only produced equivocal results.
For many years, MDMA research had been biased towards
showing the neurotoxic effects of the drug while ignoring
the clinical applications. The shifts in policies are reassuring and could not have come at a more critical time.
5
Volume 00 (00), Xxxx – Xxxx 2015
465
470
Amoroso
475
480
485
490
495
Mechanisms of MDMA-Assisted Psychotherapy
The prevalence rate for PTSD in the general population is 7.8% and 13.8% amongst veterans (Kessler et al.
1995). However, these figures may be largely underestimated due to many veterans unaccounted for or not
reporting symptoms due to stigmatization. The economic
burden of PTSD and other anxiety disorders is estimated to
cost 43.2 billion dollars annually (Greenberg et al. 1999).
More importantly, a recent report from the Veteran Affairs
claims that an average of 22 veterans are dying by suicide each day (Carney 2014). This statistic acknowledges
some serious shortcomings in the treatment options available for PTSD. Clearly, new therapeutic developments are
needed. The current pharmacotherapies available, which
are generally SSRIs, are only effective in treating 20 to
30% of patients with PTSD (Stein, Ipser, and McAnda
2009). Psychotherapeutic options are effective but intolerable by some patients due to the emotionally taxing nature
of exposure therapies. Specifically, PE is one of the most
intolerable psychotherapeutic options and is only practiced
by a small minority of Veteran Affairs clinicians (Shiner
et al. 2013). Other options, such as CPT and EMDR,
are emerging but have not been as extensively studied
as PE.
The nature of PTSD (avoidance, hyper-arousal, and reexperiencing symptoms) makes therapy inherently difficult
for patients. Patients suffer from emotional numbing due to
avoidance patterns or become hyper-aroused (anxious) due
to re-experiencing their traumas. MDMA, resulting from its
acute positive psychological effects, may be able to break
this debilitating cycle. Patients find that the reduced anxiety
caused by MDMA allows them to investigate their traumas without becoming hyper-aroused. Also, the feelings of
trust, which are mediated by oxytocin release, allow for the
patient to feel more comfortable in sharing intimate details
of his or her trauma. One other contributing factor may
be the amphetamine-like effects of the drug. Talk therapy,
especially when oriented around trauma, can be exhausting,
which causes patients to become hypo-aroused or disinterested. The amphetamine-like effects allow the patient to
remain engaged during longer therapy sessions.
Preliminary results from the two completed MDMAassisted psychotherapy clinical trials show promising
results. More research is needed to solidify these findings
and to further develop the treatment. The economic and
social costs of PTSD demand that innovative and promising treatments become available to the many suffering from
PTSD.
ORCID
Timothy Amoroso, B.S.
0003-2727-8785
500
505
510
515
520
http://orcid.org/0000-
REFERENCES
525
530
535
540
545
550
Back-Madruga, C., K. B. Boone, L. Chang, C. S. Grob, A. Lee,
H. Nations, and R. E. Poland. 2003. Neuropsychological effects
of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in
recreational users. The Clinical Neuropsychologist 17 (4):446–59.
doi:10.1076/clin.17.4.446.27939.
Bedi, G., K. L. Phan, M. Angstadt, and H. De Wit. 2009. Effects of
MDMA on sociability and neural response to social threat and
social reward. Psychopharmacology 207 (1):73–83. doi:10.1007/
s00213-009-1635-z.
Bradley, R., J. Greene, E. Russ, L. Dutra, and D. Westen. 2014. A multidimensional meta-analysis of psychotherapy for PTSD. American
Journal of Psychiatry 162 (2):214–27.
Bremner, J. D., E. Vermetten, C. Schmahl, V. Vaccarino, M. Vythilingam,
N. Afzal, and D. S. Charney. 2005. Positron emission tomographic
imaging of neural correlates of a fear acquisition and extinction
paradigm in women with childhood sexual-abuse-related posttraumatic stress disorder. Psychological Medicine 35 (06):791–806.
doi:10.1017/S0033291704003290.
Callaway, C. W., L. L. Wing, and M. A. Geyer. 1990. Serotonin
release contributes to the locomotor stimulant effects of
3, 4-methylenedioxymethamphetamine in rats. Journal of
Pharmacology and Experimental Therapeutics 254 (2):
456–64.
Carhart-Harris, R. L., M. B. Wall, D. Erritzoe, M. Kaelen, B. Ferguson,
I. De Meer, and D. J. Nutt. 2014. The effect of acutely
administered MDMA on subjective and BOLD-fMRI responses
to favourite and worst autobiographical memories. International
Journal of Neuropsychopharmacology 17 (4):527–40. doi:10.1017/
S1461145713001405.
Journal of Psychoactive Drugs
Carney, J. 2014. How can government battle a “suicide epidemic” among
veterans? TIME. June 30, 2015.
Chabrol, H. 2013. MDMA assisted psychotherapy found to have
a large effect for chronic post-traumatic stress disorder.
Journal of Psychopharmacology 27 (9):865–66. doi:10.1177/
0269881113495119.
Cloitre, M. 2009. Effective psychotherapies for posttraumatic stress disorder: A review and critique. CNS Spectrums 14 (1):32–43.
Davidson, P. R., and K. C. Parker. 2001. Eye movement desensitization and reprocessing (EMDR): A meta-analysis. Journal
of Consulting and Clinical Psychology 69 (2):305. doi:10.1037/
0022-006X.69.2.305.
Commins, D. L, G. Vosmer, R. M. Virus, W. L. Woolverton, C. R.
Schuster, and L. S. Seiden. 1987. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to
neurons in the rat brain. Journal of Pharmacology and Experimental
Therapeutics 241 (1):338–45.
de la Torre, R., and M. Farré. 2004. Neurotoxicity of MDMA
(ecstasy): The limitations of scaling from animals to humans.
Trends in Pharmacological Sciences 25 (10):505–08. doi:10.1016/
j.tips.2004.08.001.
De Win, M. M., G. Jager, H. K. Vervaeke, T. Schilt, L. Reneman, J.
Booij, and W. Van Den Brink. 2005. The Netherlands XTC Toxicity
(NeXT) study: Objectives and methods of a study investigating causality, course, and clinical relevance. International Journal
of Methods in Psychiatric Research 14 (4):167–85. doi:10.1002/
mpr.6.
Doblin, R. 2002. A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): Partnering with the
6
Volume 00 (00), Xxxx – Xxxx 2015
555
560
565
570
575
580
Amoroso
585
590
595
600
605
610
615
620
625
630
635
640
645
Mechanisms of MDMA-Assisted Psychotherapy
Mithoefer, M., L. Jerome, and R. Doblin. 2003. MDMA (“ecstasy”)
and neurotoxicity. Science 300 (5625):1504–05. doi:10.1126/
science.300.5625.1504
Mithoefer, M. C., L. Jerome, and J. M. Ruse. 2011. MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder: A
revised teaching manual draft.
Mithoefer, M. C., M. T. Wagner, A. T. Mithoefer, L. Jerome,
and R. Doblin. 2011. The safety and efficacy of±3,4methylenedioxymethamphetamine-assisted
psychotherapy
in subjects with chronic, treatment-resistant posttraumatic
stress disorder: The first randomized controlled pilot study.
Journal of Psychopharmacology 25 (4):439–52. doi:10.1177/
0269881110378371.
Mithoefer, M. C., M. T. Wagner, A. T. Mithoefer, L. Jerome, S. F.
Martin, B. Yazar-Klosinski, and R. Doblin. 2012. Durability
of improvement in posttraumatic stress disorder symptoms
and absence of harmful effects or drug dependency after
3,4-methylenedioxymethamphetamine-assisted
psychotherapy: A prospective long-term follow-up study. Journal of
Psychopharmacology 20 (1):28–39.
Monson, C. M., P. P. Schnurr, P. A. Resick, M. J. Friedman, Y. Young-Xu,
and S. P. Stevens. 2006. Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. Journal of
Consulting and Clinical Psychology 74 (5):898–907. doi:10.1037/
0022-006X.74.5.898.
Moras, K., and H. H. Strupp. 1982. Pretherapy interpersonal
relations, patients’ alliance, and outcome in brief therapy.
Archives of General Psychiatry 39 (4):405–09. doi:10.1001/
archpsyc.1982.04290040019003.
Nichols, D. E., and R. Oberlender. 1990. Structure-activity relationships
of mdma and related compounds: A new class of psychoactive
drugs? Annals of the New York Academy of Sciences 600 (1):613–23.
doi:10.1111/j.1749-6632.1990.tb16914.x.
Oehen, P., R. Traber, V. Widmer, and U. Schnyder. 2012.
A randomized, controlled pilot study of MDMA (±3,4methylenedioxymethamphetamine)-assisted psychotherapy for
treatment of resistant, chronic Post-Traumatic Stress Disorder
(PTSD). Journal of Psychopharmacology 27 (1):40–52.
Pahnke, W. N., A. A. Kurland, S. Unger, C. Savage, and S. Grof. 1971. The
experimental use of psychedelic (LSD) psychotherapy. International
Journal of Clinical Pharmacology 4:446–54.
Parrott, A. 2013. Human psychobiology of MDMA or “ecstasy”:
An overview of 25 years of empirical research. Human
Psychopharmacology: Clinical and Experimental 28:289–307.
doi:10.1002/hup.2318.
Pentney, A. R. 2001. An exploration of the history and controversies
surrounding MDMA and MDA. Journal of Psychoactive Drugs 33
(3):213–21. doi:10.1080/02791072.2001.10400568.
Pollack, M. H., K. T. Brady, R. D. Marshall, and R. Yehuda. 2001. Trauma
and stress: Diagnosis and treatment. Journal of Clinical Psychiatry
62 (11):906–15. doi:10.4088/JCP.v62n1113.
Ramos, L., C. Hicks, R. Kevin, A. Caminer, R. Narlawar, M. Kassiou,
and I. S. McGregor. 2013. Acute prosocial effects of oxytocin
and vasopressin when given alone or in combination with 3, 4methylenedioxymethamphetamine in rats: Involvement of the V1A
receptor. Neuropsychopharmacology 38 (11):2249–59. doi:10.1038/
npp.2013.125.
Ricaurte, G. A., J. Yuan, G. Hatzidimitriou, B. J. Cord, and U. D. McCann.
2002. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“ecstasy”). Science 297
(5590):2260–63. doi:10.1126/science.1074501.
Riedlinger, J. E., and D. Montagne. 2001. Using MDMA in the treatment
of depression: Ecstasy: The complete guide. Rochester, NY: Park
Street Press.
FDA. Journal of Psychoactive Drugs 34 (2):185–94. doi:10.1080/
02791072.2002.10399952.
Doukas, A., W. D’Andrea, J. Doran, and N. Pole. 2014.
Psychophysiological predictors of working alliance among
treatment-seeking women with complex trauma exposure. Journal
of Traumatic Stress 27 (6):672–79. doi:10.1002/jts.21968.
Dumont, G. J. H., F. C. G. J. Sweep, R. van der Steen, R.
Hermsen, A. R. T. Donders, D. J. Touw, and R. J. Verkes.
2009. Increased oxytocin concentrations and prosocial feelings
in humans after ecstasy (3, 4-methylenedioxymethamphetamine)
administration. Social Neuroscience 4 (4):359–66. doi:10.1080/
17470910802649470.
Foa, E. B., and M. J. Kozak. 1986. Emotional processing of fear: Exposure
to corrective information. Psychological Bulletin 99 (1):20–35.
doi:10.1037/0033-2909.99.1.20.
Gomes-Schwartz, B. 1978. Effective ingredients in psychotherapy:
Prediction of outcome from process variables. Journal of
Consulting and Clinical Psychology 46 (5):1023–35. doi:10.1037/
0022-006X.46.5.1023.
Green, A. R., A. J. Cross, and G. M. Goodwin. 1995. Review
of the pharmacology and clinical pharmacology of 3,4methylenedioxymethamphetamine
(MDMA
or
“ecstasy”).
Psychopharmacology 119 (3):247–60. doi:10.1007/BF02246288.
Greenberg, P. E., T. Sisitsky, R. C. Kessler, S. N. Finkelstein, E. R.
Berndt, J. R. Davidson, and A. J. Fyer. 1999. The economic burden
of anxiety disorders in the 1990s. Journal of Clinical Psychiatry.
doi:10.4088/JCP.v60n0702.
Grinspoon, L., and J. B. Bakalar. 1986. Can drugs be used to enhance
the psychotherapeutic process? American Journal Psychotherapy
40:393–404.
Gudelsky, G. A., and J. F. Nash. 1996. Carrier-mediated release of
serotonin by 3, 4-methylenedioxymethamphetamine: Implications
for serotonin-dopamine interactions. Journal of Neurochemistry 66
(1):243–49. doi:10.1046/j.1471-4159.1996.66010243.x.
Halpern, J. H., H. G. Pope, A. R. Sherwood, S. Barry, J. I.
Hudson, and D. Yurgelun-Todd. 2004. Residual neuropsychological
effects of illicit 3, 4-methylenedioxymethamphetamine (MDMA)
in individuals with minimal exposure to other drugs. Drug and
Alcohol Dependence 75 (2):135–47. doi:10.1016/j.drugalcdep.2004.
02.008.
Kessler, R. C., A. Sonnega, E. Bromet, M. Hughes, and C. B. Nelson.
1995. Posttraumatic stress disorder in the national comorbidity survey. Archives of General Psychiatry 52 (12):1048–60. doi:10.1001/
archpsyc.1995.03950240066012.
Liechti, M. E., C. Baumann, A. Gamma, and F. X.
Vollenweider. 2000a. Acute psychological effects of 3,4methylenedioxymethamphetamine (MDMA, “ecstasy”) are
attenuated by the serotonin uptake inhibitor citalopram.
Neuropsychopharmacology 22 (5):513–21. doi:10.1016/S0893133X(99)00148-7.
Liechti, M. E., M. R. Saur, A. Gamma, D. Hell, and F. X.
Vollenweider. 2000b. Psychological and physiological effects of
MDMA (“ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23
(4):396–404. doi:10.1016/S0893-133X(00)00126-3.
Liechti, M. E., and F. X. Vollenweider. 2000a. Acute psychological and
physiological effects of MDMA (“ecstasy”) after haloperidol pretreatment in healthy humans. European Neuropsychopharmacology
10 (4):289–95. doi:10.1016/S0924-977X(00)00086-9.
Liester, M. B., C. S. Grob, G. L. Bravo, and R. N.
Walsh. 1992. Phenomenology and sequelae of 3,4methylenedioxymethamphetamine use. The Journal of Nervous
and Mental Disease 180 (6):345–52. doi:10.1097/00005053-1992
06000-00001.
Journal of Psychoactive Drugs
7
Volume 00 (00), Xxxx – Xxxx 2015
650
655
660
665
670
675
680
685
690
695
700
705
Amoroso
715
720
725
730
735
Rosenbaum, M., and R. Doblin. 1991. Why MDMA should not have been
made illegal: The drug legalization debate, 135–46. Newbury Park,
CA: Sage Publications.
Schilt, T., M. M. de Win, G. Jager, M. W. Koeter, N. F. Ramsey,
B. Schmand, and W. van den Brink. 2008. Specific effects of
ecstasy and other illicit drugs on cognition in poly-substance
users. Psychological Medicine 38 (09):1309–17. doi:10.1017/
S0033291707002140.
Schmidt, C. J. 1987. Neurotoxicity of the psychedelic amphetamine,
methylenedioxymethamphetamine. Journal of Pharmacology and
Experimental Therapeutics 240 (1):1–7.
Seal, K. H., S. Maguen, B. Cohen, K. S. Gima, T. J. Metzler, L. Ren, and
C. R. Marmar. 2010. VA mental health services utilization in Iraq
and Afghanistan veterans in the first year of receiving new mental
health diagnoses. Journal of Traumatic Stress 23 (1):5–16.
Sessa, B., and D. J. Nutt. 2007. MDMA, politics and medical
research: Have we thrown the baby out with the bathwater? Journal of Psychopharmacology 21 (8):787–91. doi:10.1177/
0269881107084738.
Shiner, B., L. W. D’Avolio, T. M. Nguyen, M. H. Zayed, Y. Young-Xu, R.
A. Desai, and B. V. Watts. 2013. Measuring use of evidence based
psychotherapy for posttraumatic stress disorder. Administration and
Policy in Mental Health and Mental Health Services Research 40
(4):311–18. doi:10.1007/s10488-012-0421-0.
Shulgin, A. T. 1986. The background and chemistry of MDMA.
Journal of Psychoactive Drugs 18 (4):291–304. doi:10.1080/
02791072.1986.10472361.
Journal of Psychoactive Drugs
Mechanisms of MDMA-Assisted Psychotherapy
710 Shulgin, A. T., and D. E. Nichols. 1978. Characterization of three new
psychotomimetics: The Pharmacology of Hallucinogens. New York:
Pergamon.
Stanley, M., L. Traskman-Bendz, and K. Dorovini-Zis. 1985. Correlations
between aminergic metabolites simultaneously obtained from
human CSF and brain. Life Sciences 37 (14):1279–86. doi:10.1016/
0024-3205(85)90242-5.
Stein, D. J., J. Ipser, and N. McAnda. 2009. Pharmacotherapy of posttraumatic stress disorder: A review of meta-analyses and treatment
guidelines. CNS Spectrums 14:25–31.
Stolaroff, M. J. 1997. The secret chief revealed: Conversations
with a pioneer of the underground psychedelic therapy movement. Multidisciplinary Association for Psychedelic Studies
(MAPS).
Thompson, M. R., P. D. Callaghan, G. E. Hunt, J. L. Cornish,
and I. S. McGregor. 2007. A role for oxytocin and 5-HT 1A
receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience 146 (2):509–14. doi:10.1016/
j.neuroscience.2007.02.032.
Van Etten, M. L., and S. Taylor. 1998. Comparative efficacy of treatments for post-traumatic stress disorder: A meta-analysis. Clinical
Psychology and Psychotherapy 5:126–44.
Wode-Helgodt, B., and G. Sedvall. 1978. Correlations between
height of subject and concentrations of monoamine metabolites in cerebrospinal fluid from psychotic men and
women. Communications in Psychopharmacology 2 (2):
177–83.
8
Volume 00 (00), Xxxx – Xxxx 2015
740
745
750
755
760